Comparative antiproliferative and cytotoxic profile of bevacizumab (Avastin), pegaptanib (Macugen) and ranibizumab (Lucentis) on different ocular cells. [electronic resource]
Producer: 20080411Description: 1837-42 p. digitalISSN:- 0721-832X
- Angiogenesis Inhibitors -- toxicity
- Animals
- Antibodies, Monoclonal -- toxicity
- Antibodies, Monoclonal, Humanized
- Aptamers, Nucleotide -- toxicity
- Bevacizumab
- Cell Proliferation -- drug effects
- Cell Survival
- Cells, Cultured
- Choroid -- blood supply
- DNA -- biosynthesis
- Endothelium, Vascular -- drug effects
- Enzyme-Linked Immunosorbent Assay
- Humans
- Immunohistochemistry
- Materials Testing
- Pigment Epithelium of Eye -- drug effects
- Ranibizumab
- Rats
- Retinal Ganglion Cells -- drug effects
- Swine
- Vascular Endothelial Growth Factor A -- antagonists & inhibitors
- Vascular Endothelial Growth Factor Receptor-1 -- metabolism
- Vascular Endothelial Growth Factor Receptor-2 -- metabolism
- von Willebrand Factor -- metabolism
No physical items for this record
Publication Type: Comparative Study; Journal Article
There are no comments on this title.
Log in to your account to post a comment.